Company Overview
For personal use only
IHL-675A Novel multi-use drug candidate
Pulmonary inflammation model
Mice were treated with IHL-675A, CBD or Hydroxychloroquine
("HCQ") prior to induction of pulmonary inflammation. Lung fluid
was collected and analyzed for inflammatory markers.
Relative inhibition (%)
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
CBD
IL-6
HCQ
IHL-675A
Relative inhibition (%)
Incannex
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
CBD
WBC
HCQ
IHL-675A treated animals had a greater
reduction in inflammatory markers in lung fluid,
including white blood cells and the cytokine
IL-6, than animals treated with either CBD or
HCQ alone. This pattern was observed for
other inflammatory cytokines.
This indicates IHL-675A has the potential
to treat lung inflammation.
IHL-675A
Rheumatoid arthritis model
Rheumatoid arthritis was induced in rats for 17 days followed by
treatment with IHL-675A, CBD or HCQ for 14 days. Joints were
monitored for swelling during the treatment period and at the end of
the study the joint tissue was analyzed for damage via microscopy.
Relative reduction (9)
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Clinical Score Day 24
CBD
HCQ
IHL-675A
Relative reduction (%)
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Total Histology Score
CBD
HCQ
IHL-675A
IHL-675A treated animals had a greater
reduction in clinical score, a composite based
on joint swelling and the histology score, which
is a composite based on post-mortem analysis
of joint tissue, than animals treated with either
CBD or HCQ alone.
This indicates IHL-675A has the potential
to treat rheumatoid arthritis.
Inflammatory bowel disease model
To assess the potential for IHL-675A in treatment of inflammatory bowel
disease an mouse ulcerative colitis model was used. Colitis was induced
prior to treatment with IHL-675A, CBD or HCQ. On day 5, the mice were
sacrificed and the colon removed for analysis.
Relative reduction (%)
50.0
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
CBD
Colitis index
HCQ
IHL-675A
Relative reduction (96)
Lead Assets 2,3 & 4 of 10
●●●●000000
20.0
18.0
16.0
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
Macro damage score
CBD
HCQ
Animals treated with IHL-675A had a greater
reduction in macroscopic damage score
and colitis index, a composite measure of
the microscopic damage indicative of colitis
severity, than animals treated with either
CBD or HCQ.
This indicates IHL-675A has the potential
to treat inflammatory bowel disease.
IHL-675A
Investor Presentation
20View entire presentation